FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1975426515> ?p ?o ?g. }

• W1975426515 endingPage "680" @default.
• W1975426515 startingPage "677" @default.
• W1975426515 abstract "Breathing low concentrations of nitric oxide (NO) produces selective pulmonary vasodilatation and increases exercise capacity in patients with pulmonary hypertension of various etiologies, 1 Frostell C.G. Blomqvist H. Hedenstierna G. Lundberg J. Zapol W.M. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology. 1993; 78: 427-435 Crossref PubMed Scopus (390) Google Scholar , 2 Hasuda T. Satoh T. Shimouchi A. Sakamaki F. Kyotani S. Matsumoto T. Goto Y. Nakanishi N. Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension. Circulation. 2000; 101: 2066-2070 Crossref PubMed Scopus (44) Google Scholar and an acute pulmonary vasodilator response to NO inhalation has been used as a predictor of response to oral vasodilators. 3 Cockrill B.A. Kacmarek R.M. Fifer M.A. Bigatello L.M. Ginns L.C. Zapol W.M. Semigran M.J. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest. 2001; 119: 128-136 Crossref PubMed Scopus (53) Google Scholar Continuous or intermittent NO inhalation has been proposed as chronic pulmonary vasodilator therapy; 4 Channick R.N. Newhart J.W. Johnson F.W. Williams P.J. Auger W.R. Fedullo P.F. Moser K.M. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension an ambulatory delivery system and initial clinical tests. Chest. 1996; 109: 1545-1549 Crossref PubMed Scopus (169) Google Scholar however, many patients with pulmonary hypertension do not have a pulmonary vasodilator response to inhaled NO, and in patients who do respond, the duration of vasodilatation after cessation of NO inhalation is brief. Inhaled NO exerts its pulmonary vasodilator effects by diffusing into pulmonary vascular smooth muscle cells and stimulating the production of cyclic guanosine 3′-5′ monophosphate, a mediator of vasodilatation. 5 Steudel W. Hurford W.E. Zapol W.M. Inhaled nitric oxide basic biology and clinical applications. Anesthesiology. 1999; 91: 1090-1121 Crossref PubMed Scopus (133) Google Scholar One approach to augment and prolong the pulmonary vasodilator effects of inhaled NO is the concomitant administration of an inhibitor of cyclic guanosine 3′-5′ monophosphate metabolism. Sildenafil is a selective inhibitor of type 5 phosphodiesterase, a phosphodiesterase isoenzyme that metabolizes cyclic guanosine 3′-5′ monophosphate specifically and is present in pulmonary vascular smooth muscle cells. 6 Corbin J.D. Francis S.H. Cyclic GMP phosphodiesterase-5 target of sildenafil. J Biol Chem. 1999; 274: 13729-13732 Crossref PubMed Scopus (460) Google Scholar Our laboratory has recently reported that sildenafil is a selective pulmonary vasodilator in lambs with experimental pulmonary hypertension. 7 Weimann J. Ullrich R. Hromi J. Fujino Y. Clark M.W. Bloch K.D. Zapol W.M. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology. 2000; 92: 1702-1712 Crossref PubMed Scopus (202) Google Scholar Several case reports have suggested that sildenafil has pulmonary vasodilator effects in humans, 8 Prasad S. Wilkinson J. Gatzoulis M.A. Sildenafil in primary pulmonary hypertension. N Engl J Med. 2000; 343: 1342 Crossref PubMed Scopus (306) Google Scholar , 9 Zhao L. Mason N.A. Morrell N.W. Kojonazarov B. Sadykov A. Maripov A. Mirrakhimov M.M. Aldashev A. Wilkins M.R. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001; 104: 424-428 Crossref PubMed Scopus (421) Google Scholar , 10 Wilkens H. Guth A. Konig J. Forestier N. Cremers B. Hennen B. Bohm M. Sybrecht G.W. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001; 104: 1218-1222 Crossref PubMed Scopus (367) Google Scholar that it can augment the pulmonary vasodilator effects of inhaled NO, 11 Bigatello L.M. Hess D. Dennehy K.C. Medoff B.D. Hurford W.E. Sildenafil can increase the response to inhaled nitric oxide. Anesthesiology. 2000; 92: 1827-1829 Crossref PubMed Scopus (60) Google Scholar and that it can prevent rebound pulmonary hypertension after cessation of NO inhalation. 12 Atz A.M. Wessel D.L. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999; 91: 307-310 Crossref PubMed Scopus (301) Google Scholar , 13 Mychaskiw G. Sachdev V. Heath B.J. Sildenafil (Viagra) facilitates weaning of inhaled nitric oxide following placement of a biventricular-assist device. J Clin Anesth. 2001; 13: 218-220 Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar In this report, we describe hemodynamic effects of sildenafil administered alone and in combination with inhaled NO in a series of adult patients with primary pulmonary hypertension." @default.
• W1975426515 created "2016-06-24" @default.
• W1975426515 creator A5000295012 @default.
• W1975426515 creator A5007593170 @default.
• W1975426515 creator A5032643839 @default.
• W1975426515 creator A5038080550 @default.
• W1975426515 creator A5041126134 @default.
• W1975426515 creator A5041302143 @default.
• W1975426515 creator A5073059702 @default.
• W1975426515 creator A5079698562 @default.
• W1975426515 date "2002-09-01" @default.
• W1975426515 modified "2023-10-13" @default.
• W1975426515 title "Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension" @default.
• W1975426515 cites W1971406218 @default.
• W1975426515 cites W1986860141 @default.
• W1975426515 cites W2031197996 @default.
• W1975426515 cites W2031480665 @default.
• W1975426515 cites W2039058877 @default.
• W1975426515 cites W2045150258 @default.
• W1975426515 cites W2065190526 @default.
• W1975426515 cites W2072597464 @default.
• W1975426515 cites W2073590270 @default.
• W1975426515 cites W2084840888 @default.
• W1975426515 cites W2094151199 @default.
• W1975426515 cites W2153625446 @default.
• W1975426515 cites W2160314451 @default.
• W1975426515 cites W2165261476 @default.
• W1975426515 cites W2326860105 @default.
• W1975426515 cites W2336538695 @default.
• W1975426515 cites W2338144962 @default.
• W1975426515 doi "https://doi.org/10.1016/s0002-9149(02)02586-9" @default.
• W1975426515 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12231108" @default.
• W1975426515 hasPublicationYear "2002" @default.
• W1975426515 type Work @default.
• W1975426515 sameAs 1975426515 @default.
• W1975426515 citedByCount "156" @default.
• W1975426515 countsByYear W19754265152012 @default.
• W1975426515 countsByYear W19754265152013 @default.
• W1975426515 countsByYear W19754265152014 @default.
• W1975426515 countsByYear W19754265152015 @default.
• W1975426515 countsByYear W19754265152016 @default.
• W1975426515 countsByYear W19754265152017 @default.
• W1975426515 countsByYear W19754265152019 @default.
• W1975426515 countsByYear W19754265152021 @default.
• W1975426515 crossrefType "journal-article" @default.
• W1975426515 hasAuthorship W1975426515A5000295012 @default.
• W1975426515 hasAuthorship W1975426515A5007593170 @default.
• W1975426515 hasAuthorship W1975426515A5032643839 @default.
• W1975426515 hasAuthorship W1975426515A5038080550 @default.
• W1975426515 hasAuthorship W1975426515A5041126134 @default.
• W1975426515 hasAuthorship W1975426515A5041302143 @default.
• W1975426515 hasAuthorship W1975426515A5073059702 @default.
• W1975426515 hasAuthorship W1975426515A5079698562 @default.
• W1975426515 hasConcept C120770815 @default.
• W1975426515 hasConcept C126322002 @default.
• W1975426515 hasConcept C164705383 @default.
• W1975426515 hasConcept C2776768464 @default.
• W1975426515 hasConcept C2776954882 @default.
• W1975426515 hasConcept C2780930700 @default.
• W1975426515 hasConcept C42219234 @default.
• W1975426515 hasConcept C519581460 @default.
• W1975426515 hasConcept C71924100 @default.
• W1975426515 hasConceptScore W1975426515C120770815 @default.
• W1975426515 hasConceptScore W1975426515C126322002 @default.
• W1975426515 hasConceptScore W1975426515C164705383 @default.
• W1975426515 hasConceptScore W1975426515C2776768464 @default.
• W1975426515 hasConceptScore W1975426515C2776954882 @default.
• W1975426515 hasConceptScore W1975426515C2780930700 @default.
• W1975426515 hasConceptScore W1975426515C42219234 @default.
• W1975426515 hasConceptScore W1975426515C519581460 @default.
• W1975426515 hasConceptScore W1975426515C71924100 @default.
• W1975426515 hasIssue "6" @default.
• W1975426515 hasLocation W19754265151 @default.
• W1975426515 hasLocation W19754265152 @default.
• W1975426515 hasOpenAccess W1975426515 @default.
• W1975426515 hasPrimaryLocation W19754265151 @default.
• W1975426515 hasRelatedWork W1558132769 @default.
• W1975426515 hasRelatedWork W1989128070 @default.
• W1975426515 hasRelatedWork W2008435861 @default.
• W1975426515 hasRelatedWork W2016646568 @default.
• W1975426515 hasRelatedWork W2022921924 @default.
• W1975426515 hasRelatedWork W2068613360 @default.
• W1975426515 hasRelatedWork W2120941518 @default.
• W1975426515 hasRelatedWork W2260765785 @default.
• W1975426515 hasRelatedWork W2885152735 @default.
• W1975426515 hasRelatedWork W2100755299 @default.
• W1975426515 hasVolume "90" @default.
• W1975426515 isParatext "false" @default.
• W1975426515 isRetracted "false" @default.
• W1975426515 magId "1975426515" @default.
• W1975426515 workType "article" @default.